On a production line running calcium acetate monohydrate tablets for hyperphosphataemia, the first observed deviation is not press speed but granule moisture stratification during storage in unlined intermediate bulk containers. The API received as monohydrate is tested for loss on drying under USP <731>, with residual water controlled before dry granulation because aqueous wet granulation is generally avoided for this freely water-soluble salt. Dry granulation is carried out on a roller compactor equipped with 300 mm rolls and a variable gap of 2.0–4.0 mm; milled ribbons screened through 1.0 mm produce granules with bulk density of 0.55–0.75 g/mL. Densification below 0.50 g/mL reduces tablet hardness at a fixed compression force, while densification above 0.80 g/mL slows disintegration in 0.1 N HCl. Compression uses a 27-station rotary tablet press with precompression at 8–12 kN and main compression at 18–25 kN. Tablets are maintained at hardness 80–140 N and friability below 1.0% per USP <1216>. The most frequent batch failure occurs when residual granule moisture exceeds 3.5% w/w at compression; powder adheres to the lower punch face and die bore wall, producing picking and edge defects. Compression suites are therefore held below 45% relative humidity, and at-line near-infrared moisture measurement is used before loading the press hopper.

Finished calcium acetate tablets labelled at 667 mg active moiety are tested under USP <711> apparatus II at 50 rpm in 900 mL of 0.1 N HCl at 37 ± 2 °C; a common acceptance criterion is 75% released within 30 min. Uniformity of dosage units follows USP <905> with an acceptance value not exceeding 15. The phosphate-binding application depends on rapid release of calcium ions in the stomach and proximal duodenum. In-process phosphate-binding tests incubate the disintegrated tablet powder in 0.1 N HCl containing 5.0 mmol/L phosphate at 37 °C for 60 min; residual phosphate is quantified by ion chromatography. Storage limits include controlled room temperature below 30 °C. Exposure to humidity above 60% during bottle filling can initiate surface hydration of the tablet core, increasing disintegration time by 30–60 s in stability samples. A film coat is frequently omitted because the tablet is administered in multiple-tablet regimens and any gastric-release lag reduces phosphate-binding efficiency. When a seal coat is required, a low-viscosity hydroxypropyl methylcellulose system applied to 3.0–4.0% w/w weight gain is preferred over polyvinyl alcohol-based barrier coats that may increase disintegration lag in aged samples.

What Terminal Sterilisation Variables Govern Sodium Acetate Injection pH Stability?

Bulk preparation of 2 mEq/mL sodium acetate injection starts with 164 mg/mL sodium acetate anhydrous dissolved in Water for Injection at 35–40 °C. Dissolution of the acetate salt is endothermic at lower temperatures and can extend mixing beyond 4 h in a 500 L stainless steel compounding vessel. The solution pH is adjusted to 6.0–7.5 with glacial acetic acid before filtration through a 0.22 µm polyethersulfone filter cartridge. Terminal sterilisation at 121 °C for 15 min is the standard cycle for 10 mL single-dose vials. Because acetate buffer equilibrium is temperature-dependent, pH after autoclaving is commonly 0.2–0.3 units lower than pre-sterilisation value. Bulk solution is therefore adjusted to the upper half of the compendial range before steam sterilisation. Fill volume is set at 10.5 mL to allow for thermal expansion during autoclaving and to meet routable dose withdrawal expectations under USP <1151>.

Particulate matter is controlled under USP <788> using light obscuration particle counting; visible particulates are assessed under USP <790>. Bacterial endotoxins are tested per USP <85>, and sterility per USP <71> with membrane filtration. Production-scale failures frequently involve vial headspace oxygen and trace aldehyde formation from acetate decomposition under terminal heat; vials are flushed with nitrogen to maintain residual oxygen below 2.0% before stoppering. The hypertonic solution has an osmolarity of approximately 4 mOsmol/mL and must be diluted before intravenous administration. It should not be combined directly with phosphate-containing admixtures unless compatibility has been established because calcium and phosphate salts can precipitate at final admixture pH above 6.0. Long-term storage is at 20–25 °C with controlled excursions provided by stability data. Freezing is avoided because crystallisation can occur and reheating may not restore homogeneity.

Because zinc acetate dihydrate remains ionised at gastric pH, a 25 mg or 50 mg capsule formulation for Wilson’s disease must release its content in 0.1 N HCl before the capsule plug passes the pyloric region. Direct filling of zinc acetate dihydrate alone produces unacceptable weight variation because the API has a bulk density below 0.50 g/cm³ and poor flow under low-force dosator encapsulation. Fill blends typically include 20–40% w/w silicified microcrystalline cellulose, 0.25–0.50% w/w colloidal silicon dioxide, and 0.5–1.0% w/w magnesium stearate. A dosator-type capsule machine with pin heights set to 3.0–5.0 mm is operated at 30,000–60,000 capsules/h, with in-process weight checks every 15 min. Weight variation must remain within ±5.0% for a 50 mg fill and comply with USP <905>. Capsule shells are normally size 3 or 4 to reduce headspace and moisture ingress.

Dissolution testing under USP <711> uses 900 mL of 0.1 N HCl at 37 ± 2 °C and a typical acceptance criterion of 75% released within 30 min. The method is selected because phosphate buffer at pH 6.8 can form a surface precipitate of zinc phosphate that suppresses release in artificial intestinal media; this phenomenon is formulation-specific rather than an intrinsic API failure. Manufacturing under relative humidity above 55% leads to moisture pick-up by the capsule shell and can soften gelatin or hypromellose shells, causing dome cracking after 6–12 weeks of accelerated storage at 40 °C/75% RH. Blends are therefore prepared in rooms controlled below 40% relative humidity and packaged in PVC/PVDC/aluminium blisters rather than high-density polyethylene bottles. A 50 mg zinc acetate dihydrate capsule contains 14.9 mg elemental zinc. The prescribed regimen for Wilson’s disease maintenance is typically separated from food by at least 1 h because food-derived phytates and phosphate reduce zinc absorption and can blunt the copper-blocking effect in intestinal epithelial cells.

When Potassium Acetate Injection Enters Neonatal Parenteral Nutrition Admixture Lines

Potassium acetate concentrate at 2 mEq/mL is added to neonatal total parenteral nutrition regimens to supply potassium and to reduce chloride load when metabolic acidosis is present. The acetate anion is metabolised in the liver to bicarbonate on a 1:1 molar basis, so acetate:chloride ratios in the final admixture are adjusted in steps of 0.1–0.2 to avoid rapid shifts in acid-base status. Compounding is performed in an ISO Class 5 laminar-flow workstation under USP <797>; final admixture pH typically falls between 5.0 and 6.0. The primary stability-limiting factor is not potassium concentration but the interaction between calcium gluconate and phosphate salts. When calcium and phosphate are ordered in high concentrations, precipitation of dibasic calcium phosphate can occur at pH above 5.5; organic phosphate salts, lower final temperature, and the use of cysteine hydrochloride can shift the safe zone. The acetate salt contributes to the anionic load and must be included in ion balance calculations before batch release.

Final total parenteral nutrition admixtures are filtered through a 0.22 µm inline filter during administration; in neonatal intensive care, a 0.2 µm air-eliminating filter may be placed on the line. Visual inspection of the compounded bag is not sufficient to rule out sub-visible precipitation; turbidity measurements at 550 nm or light obscuration methods under USP <788> are used in stability evaluations. The terminal product is not heat-sterilised after compounding; therefore all components, including the potassium acetate concentrate, must pass USP <71> sterility and USP <85> bacterial endotoxin requirements before entering the mixing environment. Acetate-containing admixtures are not stored beyond the beyond-use date assigned under USP <797> for medium-risk compounded sterile preparations. Plasticised polyvinyl chloride bags can sorb potassium acetate over time; if ethylene vinyl acetate or polyolefin multi-layer bags are used, the sorption loss is below 2.0% after 48 h at 2–8 °C. A documented incompatibility exists with certain poorly buffered lipid emulsions when the emulsion is co-infused at high rates; the acetate ion can destabilise the anionic emulsifier layer if admixture pH falls below 5.0.

For lyophilised subcutaneous peptide products requiring an acetate buffer at pH 4.0–5.5, sodium acetate trihydrate is dissolved with the peptide in Water for Injection at 5–20 mmol/L, and pH is adjusted with acetic acid before sterile filtration. The critical process conflict occurs during primary drying because the acetic acid component is volatile under vacuum, whereas sodium acetate remains in the solid phase. When the freeze-dryer shelf is held at -25 °C and chamber pressure at 80–100 mTorr, a portion of the acetic acid sublimes into the condensate; this can increase the pH of the amorphous cake by 0.3–0.8 units relative to the liquid fill. Products that are pH-sensitive, such as lyophilised peptide salts, are therefore formulated with a higher proportion of the salt form and a lower proportion of free acid, or the drying cycle is shortened by reducing fill depth to ≤ 10 mm and using a lower shelf ramp rate. The lyophilised cake is expected to be white to off-white and to reconstitute in less than 3 min with Water for Injection at 20–25 °C.

Residual moisture after cycle end is controlled below 3.0% w/w by Karl Fischer titration aligned with USP <921>; cake appearance is not used as a sole release criterion because micro-collapse can occur without visible defects. Batch-to-batch pH drift in the freeze-dried solid is measured by reconstitution of the cake in 5 mL of Water for Injection and potentiometric pH determination at 25 °C. If the measured pH exceeds the specification by more than 0.2 units, the root cause is usually an undersized condenser or overload of the chamber beyond the condenser capacity of 30–40 kg of ice per 24 h in a production-scale lyophiliser. Acetate buffer salts suitable for this use must meet residue on ignition limits under USP <281> and elemental impurity controls aligned with USP <232> and USP <233>; modern parenteral API release also requires an endotoxin limit of ≤ 0.25 EU/mg. The final dosage form is a sterile lyophilised powder for subcutaneous injection after reconstitution, not a ready-to-use solution. The acetate system is selected because it provides buffering without chelating peptide cations to the same extent as citrate at low pH.

Granule Reconstitution Behaviour and Moisture Barrier Packaging for Oral Calcium Acetate Sachets

This downstream form is used when the patient cannot swallow tablets; granules are filled into single-dose sachets at 667 mg or 1334 mg calcium acetate per sachet. Granulation is performed in a fluid-bed granulator with top spray; the binder solution consists of pregelatinised maize starch and hydroxypropyl methylcellulose at 6–8% w/w solids applied until granule moisture reaches 8–10% w/w. After drying at inlet air temperature 55–65 °C, granules are sieved through 850 µm and retained above 150 µm to ensure complete dispensing from the sachet. Reconstitution in 50 mL of water at 20–25 °C produces a suspension with pH 6.5–7.5; stirring for 30 s is sufficient because calcium acetate is freely soluble and the insoluble fraction is mainly starch-based. Granules are packed in aluminium/polyethylene laminate sachets because calcium acetate monohydrate can deliquesce above 70% relative humidity; the moisture vapour transmission rate of the laminated film is less than 0.1 g/m²/day at 38 °C/90% RH.

Dose accuracy is verified by fill weight variation of ±3.0% per sachet and by dispersibility testing using a 1 L beaker with a magnetic stirrer at 100 rpm for 2 min. The final suspension is used immediately because storage of the reconstituted product at room temperature for more than 24 h can allow microbial proliferation in the starch-containing vehicle. The finished sachet product follows solid oral dosage form tests under USP <905> if individual units are considered as separate dosage forms, and is subject to microbial limits under USP <61> and USP <62> for non-sterile products. Because the terminal product is intended for hyperphosphataemia, the same phosphate-binding quality control described for tablets applies to the granule powder after reconstitution; dissolution testing is adapted from USP <711> with a first sampling point at 15 min to capture rapid release from the dispersed state.